Frontlight ResearchEarly access
TerminatedPhase 3
Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
Key facts
- Who runs it
- Pulmocide Ltd
- Where
- Ann Arbor, Baltimore, Houston, Jacksonville, La Jolla, Los Angeles, Madison, Minneapolis, Philadelphia, Pittsburgh, Sacramento, St Louis, and The Bronx, United StatesSee the 15 sitesAlso in 19 other countries, 60 sites
- Trial code
- NCT05238116
- EU 2024-511281-36-00
- EudraCT 2021-004554-32
- U1111-1304-0792
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 85 people enrolled
- Started
- 14 Jun 2022
- Ended
- 29 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- PC945
- Placebo
- Record updated
- 30 April 2026
- Why it stopped
- The study was terminated by the Sponsor based on a sample size recalculation interim analysis which showed a numerically lower favorable response rate and a numerically higher mortality rate in the opelconazole arm compared to the control arm.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Participant has proven or probable IPA according to the modified 2019 European Organization for Research and Treatment of Cancer/ Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) consensus definitions or according to the 2010 International Society for Heart and Lung Transplantation (ISHLT) consensus statements for the definitions of infections in cardiothoracic transplant recipients
- Participant's IPA has failed to respond to adequate antifungal therapy
Who cannot take part
- Participant with a known or suspected concomitant medical condition or post-surgery complication that, in the opinion of the Investigator, may jeopardize adherence to the protocol requirements or impede the accurate measurement of efficacy or may be an unacceptable additional risk to the Participant should he/she participate in the study
- Participant who has previously received PC945
- Participant with a known history of allergy, hypersensitivity, or any previous serious reaction to any component of the PC945 or placebo formulations
- Participant who has recently received, is receiving or due to receive at any time during the study, an investigational medicinal agent that does not have any regulatory approved indications. Subjects who are participating in any other trials e.g., Observational, diagnostic or using medications with an approved indication may be allowed to participate after consultation with the sponsor on an individual basis
Where in United States
Also in 19 other countries, 60 sites
- Ann Arbor, MichiganHospital not named in the registry
- Baltimore, MarylandHospital not named in the registry
- Houston, TexasHospital not named in the registry
- Houston, TexasHospital not named in the registry
- Jacksonville, FloridaHospital not named in the registry
- La Jolla, CaliforniaHospital not named in the registry
- Los Angeles, CaliforniaHospital not named in the registry
- Clinical R SiteLos Angeles, United States
- Madison, WisconsinHospital not named in the registry
- Minneapolis, MinnesotaHospital not named in the registry
- Philadelphia, PennsylvaniaHospital not named in the registry
- Pittsburgh, PennsylvaniaHospital not named in the registry
- Sacramento, CaliforniaHospital not named in the registry
- St Louis, MissouriHospital not named in the registry
- The Bronx, New YorkHospital not named in the registry
About the trial
What the trial wants to find out
To assess the safety and efficacy of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA
The 2 groups in the trial
- PC945Treatment being tested
PC945 dose, administered via nebulizer, twice daily
- PlaceboPlacebo, for comparison
PC945-placebo administered via nebulizer, twice daily
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Efficacy of Nebulized PC945 When Added to Systemic Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
- Record updated
- 30 April 2026